ERIN RADEMAN-ALONSO: Open Payments
NPI 1295249290 · CAMDENTON, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$507 in 24 payments from 9 companies in 2025. Trend: 2023 $229 · 2024 $377 · 2025 $507
Food & beverage: $507
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. | 6 | $136 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $77 |
| ABBVIE INC. | 4 | $71 |
| Novo Nordisk Inc | 3 | $64 |
| Neurocrine BioSciences, Inc. | 2 | $53 |
| Lilly USA, LLC | 2 | $34 |
| AstraZeneca Pharmaceuticals LP | 1 | $33 |
| Exact Sciences Corporation | 1 | $24 |
| PFIZER INC. | 1 | $17 |
Products named: Dexcom G6 Transmitter, CAPLYTA, INGREZZA, Wegovy, VRAYLAR, BREZTRI, Cologuard Collection Kit, UBRELVY.
Industry payments across MO — which companies pay providers there.
